Tag Archives: PD-L1

Hope for Mesothelioma? Parasite Triggers Tumor Regression in the Lab

tumor regression

A parasite found in cat feces triggered tumor regression in recent animal studies in China. It is a hopeful sign that the same process might be adapted to help human mesothelioma patients, too.   The parasite is toxoplasma gondii. It is a single-celled parasite that can only replicate inside live host cells. It is typically found in the feces of cats or in soil or water contaminated by their feces.  It is capable of entering most cells in most warm-blooded animals.  The goal of the new Chinese study was to determine whether toxoplasma gondii could modulate immune response in tumors. If it can, it might help immunotherapy drugs cause tumor regression in people with mesothelioma and other hard-to-treat cancers.  How Mesothelioma … Continue reading Hope for Mesothelioma? Parasite Triggers Tumor Regression in the Lab »

Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival

Osteopontin and Mesothelioma: Unraveling the Connection

Mesothelioma patients with higher levels of the PD-L1 protein in their tumor cells have worse overall survival compared to those with lower levels. But that may not be true for patients who have immunotherapy. That news comes from a new European study of more than 200 patients. PD-L1 and its partner protein PD-1 (found in immune system cells) are popular targets for new immunotherapy drugs. But the new study aimed to find out if they impact mesothelioma survival independently of immunotherapy. The team concluded the PD-L1 protein may shorten lifespan. PD-1 does not seem to have the same effect.  Pleural Mesothelioma and the PD-L1 Protein Pleural mesothelioma is an intractable cancer of the lung lining. It often leads to poor … Continue reading Higher PD-L1 Protein May Predict Shorter Mesothelioma Survival »

Breakthroughs in Mesothelioma in 2020

Creating an American Mesothelioma Patient Registry

In spite of a global pandemic, there were some major breakthroughs in mesothelioma in 2020 that made the year a hopeful one for people fighting asbestos cancer. Malignant mesothelioma is the most serious illness caused by exposure to asbestos fibers.  Mesothelioma is still not curable. But researchers have made major breakthroughs in mesothelioma diagnosis, prognosis, and treatment this year.  Mesothelioma Treatment Advances Mesothelioma treatment saw the biggest breakthroughs in mesothelioma in 2020. The FDA approved the first systemic treatment for mesothelioma since 2004. That was the year that Alimta (pemetrexed) received approval.  They approved a combination of the immunotherapy drugs Opdivo and Yervoy. Yervoy helps activate and proliferate T-cells. Opdivo helps existing T-cells discover the mesothelioma  tumor. The patients who … Continue reading Breakthroughs in Mesothelioma in 2020 »

High PD-L1 Levels Could Be Bad News for Mesothelioma Surgery Candidates

Yet another new study has found a link between PD-L1 levels and mesothelioma survival – this time in people slated to have surgery for malignant pleural mesothelioma.  PD-L1 stands for programmed cell death ligand 1. It is a protein expressed by some cancer cells that helps them avoid immune system attack.  Researchers at Baylor College of Medicine are the latest to show that higher PD-L1 levels may lead to a worse mesothelioma prognosis. Their study focused specifically on mesothelioma surgery candidates.  The results were published recently in the Annals of Thoracic Surgery.  PD-L1 Levels and Mesothelioma Prognosis Even healthy people express some amount of PD-L1. Its job is to suppress the part of the immune system that attacks foreign tissues. … Continue reading High PD-L1 Levels Could Be Bad News for Mesothelioma Surgery Candidates »

PD-L1 Expression and Mesothelioma Prognosis

PD-L1 expression and mesothelioma prognosis

The largest study yet on PD-L1 expression and mesothelioma prognosis shows that patients with more of this protein in their cells have poorer odds of survival. Programmed death ligand 1 (PD-L1) helps cancer cells evade immune system attack.  Other studies have suggested a link between PD-L1 expression and mesothelioma prognosis. But the new meta-analysis performed by two Chinese researchers appears to confirm it with an even bigger data set.  Understanding Mesothelioma Prognosis Malignant mesothelioma is an uncommon cancer that typically carries a poor prognosis. Many people diagnosed with mesothelioma lose their lives to the illness within a year.  But there are also many exceptions. Some mesothelioma survivors live for decades after a mesothelioma diagnosis. Australian Paul Kraus is an example. … Continue reading PD-L1 Expression and Mesothelioma Prognosis »

PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study

PD-L1 inhibitor nivolumab

A study of the PD-L1 inhibitor nivolumab showed “safety and efficacy” in mesothelioma patients who failed with other treatments.  Nivolumab is a type of immunotherapy marketed under the brand name Opdivo. It is similar to pembrolizumab (Keytruda) in that it blocks the tumor-promoting protein PD-L1. Nivolumab is most often used for patients with non-small cell lung cancer.  A multicenter phase II Japanese study found the PD-L1 inhibitor nivolumab helped a group of pleural mesothelioma patients live longer. Just as importantly, the side effects of the drug were “manageable”.  Human Trial of PD-L1 Inhibitor Nivolumab Chemotherapy with pemetrexed (Alimta) and cisplatin is the standard first-line treatment for pleural mesothelioma. But many patients either do not respond to chemotherapy or they stop … Continue reading PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study »

Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels

shorter mesothelioma linked to protein

Patients with the rarest mesothelioma subtypes tend to experience shorter mesothelioma survival. Now, new mesothelioma research suggests that may have something to do with a protein called PD-L1. French researchers studied the PD-L1 levels in the tumors of 214 mesothelioma patients. They compared the levels with each patient’s subtype and their treatment outcome.  The results may help explain cases of shorter mesothelioma survival, especially among patients with sarcomatoid or biphasic mesothelioma subtypes.  PD-L1 Levels and Shorter Mesothelioma Survival Programmed death ligand 1 (PD-L1) is one of the proteins that helps mesothelioma cells and other cancers “hide” from the immune system.  Normally, the immune system finds and destroys renegade cells. But if a patient’s mesothelioma tumor expresses higher amount of PD-L1, … Continue reading Shorter Mesothelioma Survival Again Linked to Higher PD-L1 Levels »